ong-term protection after primary yellow fever vaccination in elderly persons (60 years or older at the time of primary vaccination)

Completed

• Conditions: protection after vaccination; 10047438

• Registration Number: NL-OMON48529
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 58

Inclusion Criteria

Participation in the clinical vaccine trial in 2008-2009 (GKOUD)

Exclusion Criteria

Receipt of an extra yellow fever vaccination after participation in the GKOUD
trial

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is the percentage of participants with protective YFVNA<br /><br>titers in the elderly group compared to the younger group, ten years after<br /><br>primary vaccination. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary endpoint is the geometrical mean titre of yellow fever<br /><br>neutralizing antibodies in each study group.</p><br>